Consumption-based approach for assessing the contribution of hospitals towards the load of pharmaceutical residues in municipal wastewater

Environment International

Volumn 45, Issue 1, 2012, Pages 99-111

  Le Corre, Kristell S ^a   Ort, Christoph ^a,b   Kateley, Diana ^c   Allen, Belinda ^c   Escher, Beate I ^a   Keller, Jurg ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY   (Switzerland)

^c QUEENSLAND HEALTH   (Australia)

Author keywords

Acceptable daily intake; Audit data; Hospital wastewater; Margin of exposure; Pharmaceuticals; Source control

Indexed keywords

ANTIBIOTICS; DRUG PRODUCTS; FACTOR ANALYSIS; HEALTH RISKS; SEWAGE TREATMENT PLANTS;

ACCEPTABLE DAILY INTAKES; AUDIT DATA; HOSPITAL WASTEWATER; MARGIN OF EXPOSURE; SOURCE CONTROL;

HOSPITALS;

ALFENTANIL; AMPICILLIN; ATRACURIUM; AZTREONAM; BUPIVACAINE; CARMUSTINE; CEFAZOLIN; CYCLOPENTOLATE; DOBUTAMINE; DRINKING WATER; EPHEDRINE; FOSCARNET; ISOPRENALINE; KETAMINE; MEROPENEM; METOLAZONE; MITOMYCIN; NEOSTIGMINE; NIMODIPINE; OXYBUPROCAINE; PANCURONIUM; PIPERACILLIN; PROPOFOL; ROPIVACAINE; TAZOBACTAM; TETRACAINE; THIOPENTAL; TROPICAMIDE; VINCRISTINE;

ANTIBIOTICS; HEALTH RISK; HOSPITAL SECTOR; INDUSTRIAL WASTE; POLLUTANT SOURCE; RISK FACTOR; WASTEWATER;

ARTICLE; CONTROLLED STUDY; DRUG USE; EFFLUENT; HEALTH HAZARD; HOSPITAL WASTE; MUNICIPAL SOLID WASTE; PRIORITY JOURNAL; RESIDUE ANALYSIS; RISK ASSESSMENT; SEWAGE TREATMENT PLANT; STREAM (RIVER); TOXICITY TESTING; WASTE COMPONENT REMOVAL;

AUSTRALIA;

EID: 84860658168     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2012.03.008     Document Type: Article

References (49)

1. Aherne G.W., Hardcastle A., Nield A.H. Cytotoxic drugs and the aquatic environment: estimation of bleomycin in river and water samples. J Pharm Pharmacol 1990, 42(10):741-742.
2. Al-Ahmad A., Kümmerer K. Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment. Cancer Detect Prev 2001, 25(1):102-107.
3. AMH Australian medicine handbook 2011, Vincristine, Accessed in July 2011 at:. http://amh.hcn.net.au/view.php?page=chapter14/monographvincristine.html#vincristine.
4. Anderson A.M.L., Lennox J.L. Abacavir/Lamiduvine fixed dose combination in the treatment of patients with HIV infection. HIV Ther 2009, 3(1):19-29.
5. Besse J.-P., Latour J.-F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39(1):73-86.
6. Bruce M.G., Pleus R.C., Snyder S.A. Toxicological relevance of pharmaceuticals in drinking water. Environ Sci Technol 2010, 44(14):5619-5626.
7. Busetti F., Heitz A. Determination of human and veterinary antibiotics in indirect potable reuse systems. Int J Environ Anal Chem 2011, 91(10):989-1012.
8. Chang X., Meyer M.T., Liu X., Zhao Q., Chen H., Chen J., et al. Determination of antibiotics in sewage from hospitals, nursery and slaughter house, wastewater treatment plant and source water in Chongqing region of Three Gorge Reservoir in China. Environ Pollut 2010, 158(5):1444-1450.
9. Costanzo S.D., Watkinson A.J. Pharmaceuticals. Occasional paper 8: Chemicals of concern in wastewater treatment plant effluent: State of the science in Australia, CRC for water quality and treatment, Salisbury, Australia 2007, Available at:, Accessed: July 2011. http://www.wqra.com.au/publications/document-search/?download=24.
10. De Souza S.M.L., de Vasconcelos E.C., Dziedzic M., De Oliveira C.M.R. Environmental risk assessment of antibiotics: an intensive care unit analysis. Chemosphere 2009, 77(7):962-967.
11. Escher B.I., Baumgartner R., Koller M., Treyer K., Lienert J., McArdell C.S. Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Res 2011, 45(1):75-92.
12. Fick J., Soderstrom H., Lindberg R.H., Phan C., Tysklind M., Larsson J.D.G. Contamination of surface, ground, and drinking water from pharmaceutical production. Environ Toxicol Chem 2009, 28(12):2522-2527.
13. Gupta P., Mathur N., Bhatnagar P., Nagar P., Srivastava S. Genotoxicity evaluation of hospital wastewater. Ecotoxicol Environ Saf 2009, 72(7):1925-1932.
14. Hartmann A., Alder A.C., Koller T., Widmer R.M. Identification of fluoroquinolone antibiotics as the main source of umuC genotoxicity in native hospital wastewater. Environ Toxicol Chem 1998, 17(3):377-382.
15. Hawkshead J. Hospital wastewater containing pharmaceutically active compounds and drug resistant organisms: a source of environmental toxicity and increased antibiotic resistance. J Residuals Sci Tech 2008, 5(2):51-60.
16. Heberer T., Feldmann D. Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents-modeling versus measurements. J Hazard Mater 2005, 122(3):211-218.
17. Heberer T., Feldmann D. Erratum: Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents-modeling versus measurements. J Hazard Mater 2005, 127(1-3):249.
18. HSDP Highly specialised drugs program (Section 100) of the Australian Pharmaceutical Benefit Scheme (PBS) Available at:, Accessed: July 2011. http://www.pbs.gov.au/info/browse/section-100/s100-highly-specialised-drugs.
19. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348(1-2):167-175.
20. Kümmerer K. Drugs in the environment: Emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources-a review. Chemosphere 2001, 45(6-7):957-969.
21. Kümmerer K. Significance of antibiotics in the environment. J Antimicrob Chemother 2003, 52(1):5-7.
22. Kümmerer K. Pharmaceuticals in the environment: sources, fates, effects and risks 2004, Springer, Berlin, Germany, 527pp. Second Edition.
23. Kümmerer K., Al-Ahmad A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ Sci Pollut Res 2010, 17(2):486-496.
24. Kümmerer K., Henninger A. Promoting resistance by the emission of antibiotics from hospitals and households into effluents. Clin Microbiol Infect 2003, 9(12):1203-1214.
25. Langford K.H., Thomas K.V. Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works. Environ Int 2009, 35(5):766-770.
26. Lienert J., Güdel K., Escher B.I. Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes. Environ Sci Technol 2007, 41(12):4471-4478.
27. Lienert J., Koller M., Konrad J., McArdell C.S., Schuwirth N. Multiple-criteria decision analysis reveals high stakeholder preference to remove pharmaceuticals from hospital wastewater. Environ Sci Technol 2011, 45(9):3848-3857.
28. Lindberg R., Jarnheimer P., Olsen B., Johansson M., Tysklind M. Determination of antibiotic substances in hospital sewage water using solid phase extraction and liquid chromatography/mass spectrometry and group analogue internal standards. Chemosphere 2004, 57(10):1479-1488.
29. McArdell C.S., Kovalova L., Siegrist H., Kienle C., Moser R., Schwartz T. Input and elimination of pharmaceuticals and disinfectants from hospital wastewater. Final project report, Eawag, Duebendorf Switzerland, July 2011 2011, 95pp. Accessible at:. http://tinyurl.com/eawag-spitalabwasser.
30. MIMS Australia MIMS Online available at:, Accessed in February 2011. https://www.mimsonline.com.au.
31. Mullot J., Karolak S., Fontova A., Levi Y. Modelling of hospital wastewater pollution by pharmaceuticals: first results of Mediflux study carried out in three French hospitals. Water Sci Technol 2010, 62(12):2912-2919.
32. NRMMC Australian guidelines for water recycling: Managing health and environmental risks (Phase 2): augmentation of drinking water supplies 2008, published by, the Natural Resource Management Ministerial Council (NRMMC), the Environment and Heritage Council (EPHC) and the National Health and Medical Research Council (NHMRC), Canberra, Australia, 159pp. Available at:, Accessed: July 2011. http://www.ephc.gov.au/sites/default/files/WQ_AGWR_GL__ADWS_Corrected_Final_%20200809.pdf.
33. OECD Health care activities: pharmaceutical consumption. Health at a glance 2009: OECD indicators 2009, OECD Publishing, Paris, France, 201pp. Available at:, Accessed: July 2011. http://www.oecd.org/dataoecd/55/2/44117530.pdf.
34. Ohlsen K., Ternes T., Werner G., Wallner U., Löffler D., Ziebuhr W., et al. Impact of antibiotics on conjugational resistance gene transfer in Staphylococcus aureus in sewage. Environ Microbiol 2003, 5(8):711-716.
35. Ort C., Lawrence M.G., Reungoat J., Eaglesham G., Carter S., Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res 2010, 44(2):605-615.
36. Ort C., Lawrence M.G., Reungoat J., Mueller J.F. Sampling for PPCPs in wastewater systems: comparison of different sampling modes and optimization strategies. Environ Sci Technol 2010, 44(16):6289-6296.
37. Ort C., Lawrence M.G., Rieckermann J., Joss A. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? A critical review. Environ Sci Technol 2010, 44(16):6024-6035.
38. Pauwels B., Verstraete W. The treatment of hospital wastewater: an appraisal. J Water Health 2006, 4(4):405-416.
39. Reinthaler F.F., Posch J., Feierl G., Wüst G., Haas D., Ruckenbauer G., et al. Antibiotic resistance of E. coli in sewage and sludge. Water Res 2003, 37(8):1685-1690.
40. Runnalls Tamsin J., Margiotta-Casaluci L., Kugathas S., Sumpter J.P. Pharmaceuticals in the aquatic environment: steroids and anti-steroids as high priorities for research. Hum Ecol Risk Assess 2010, 16(6):1318-1338.
41. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface water. Regul Toxicol Pharmacol 2004, 39(2):158-183.
42. Sim W., Lee J., Lee E., Shin S., Hwang S., Oh J. Occurrence and distribution of pharmaceuticals in wastewater from households, livestock farms, hospitals and pharmaceutical manufactures. Chemosphere 2011, 82(2):179-186.
43. Ternes A.T., Giger W., Joss A. Introduction. Human pharmaceuticals, hormones and fragrances, the challenges of micropollutants in urban water management 2006, 1-13. IWA publishing, London, UK, 453pp. A.T. Ternes, A. Joss (Eds.).
44. TGA 2011. Therapeutic Goods Administration, Australia. http://www.tga.gov.au/.
45. Thomas K.V., Dye C., Schlabach M., Langford K.H. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 2007, 9(12):1410-1418.
46. Verlicchi P., Galleti A., Petrovic M., Barceló D. Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options. J Hydrol 2010, 389(3-4):416-428.
47. Watkinson A.J., Murby E.J., Kolpin D.W., Costanzo S.D. The occurrence of antibiotics in an urban watershed: from wastewater to drinking water. Sci Total Environ 2009, 407(8):2711-2723.
48. Webb S.F. A data base perspective on the environmental risk assessment of human pharmaceuticals III-indirect human exposure. Pharmaceuticals in the environment: Sources, fates, effects and risks 2004, 363-372. Springer, Berlin, Germany, 527pp. Second Edition. K. Kümmerer (Ed.).
49. Weissbrodt D., Kovalova L., Ort C., Pazhepurackel V., Moser R., Hollender J., et al. Mass flows of X-ray contrast media and cytostatics in hospital wastewater. Environ Sci Technol 2009, 43(13):4810-4817.